Close menu




May 8th, 2020 | 14:50 CEST

Allianz, Commerzbank, TUI, Wirecard - and news for investors

  • Investments
Photo credits: pixabay.com

A week on the stock market with positive price development is slowly coming to an end. The DAX was at a low of 10,426 points at the beginning of the week and currently stands at 10,837 points. The gain of more than 400 points is mainly due to the relaxation of measures to limit the spread of the Corona Pandemic. In the meantime, more and more citizens have doubts that the Federal Government has reacted appropriately in dealing with Covid-19. In retrospect, of course, people are always smarter. The fact that the opinions of medical specialists and virologists on this type of corona virus diverged widely and that politicians took the side of drastic measures may have contributed to the fact that Germany has got off so lightly so far.

time to read: 1 minutes | Author: Mario Hose
ISIN: DE0008404005 , DE000CBK1001 , DE000TUAG000 , DE0007472060

Table of contents:


    Financial institutions in focus

    The Allianz shares opened the week at around EUR 164.00 and last traded at EUR 157.84. The reason for this price decline is trading ex-dividend. The company paid a dividend of EUR 9.60 to shareholders as of May 7, 2020. All in all, it was a positive week for long-term Allianz shareholders. The Commerzbank shares are currently quoted at around EUR 3.22, as at the beginning of the week. Despite the news that Comdirect can now be taken over completely, the trading performance was relatively unspectacular.

    On the footsteps of Symrise

    The shares of EXMceuticals, the young supplier of pure ingredients for the health sector, were able to increase in trading yesterday on the Canadian home market in phases by over 100% from CAD 0.17 to CAD 0.35. The company, which is operationally based in Lisbon, Portugal, announced yesterday that it had signed a letter of intent, thus arousing the interest of investors. It is possible that a new Symrise will be created with EXMceuticals. The potential for pure ingredients and active ingredients is great and, above all, scalable.

    Opportunity before the gold boom

    Exciting for gold investors this week was the news from Osino Resources. The company is starting the 20,000 metre Twin Hills drill program and will be exploring further details of recent discoveries. CEO Heye Daun is experienced and has previously developed a company for acquisition by B2Gold in Namibia. Osino Resources' management is pursuing the same goal for its shareholders with the current work in Namibia. The share price was last quoted at CAD 0.87 and the market value of the company is around CAD 85 million. During times of aid packages for the economy, the devaluation of money will accompany this. A gold boom is only a question of time.

    Analysts make prices

    Yesterday's trading day saw TUI shares come under pressure in connection with a reduction in Morgan Stanley's price target from EUR 13 to EUR 1.30. At the beginning of the week, the tour operator's share was still trading at over EUR 3.50, but recently the shares changed hands at EUR 3.14. Uncertainty among analysts caused further price fluctuations even with downgrades at Wirecard. The DZ Bank has even temporarily suspended coverage of the DAX company. Despite an eventful week, the share price is back at around EUR 87.00, as at the beginning of the week.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read